Progyny, Inc. $PGNY Shares Sold by Pacer Advisors Inc.

Pacer Advisors Inc. reduced its position in shares of Progyny, Inc. (NASDAQ:PGNY) by 24.3% in the 4th quarter, Holdings Channel.com reports. The firm owned 291,485 shares of the company’s stock after selling 93,594 shares during the period. Pacer Advisors Inc.’s holdings in Progyny were worth $7,485,000 as of its most recent SEC filing.

Other institutional investors and hedge funds have also recently modified their holdings of the company. Caitong International Asset Management Co. Ltd purchased a new position in Progyny in the fourth quarter valued at $25,000. Hantz Financial Services Inc. raised its stake in Progyny by 79.4% in the fourth quarter. Hantz Financial Services Inc. now owns 1,676 shares of the company’s stock valued at $43,000 after buying an additional 742 shares in the last quarter. Quarry LP lifted its holdings in Progyny by 2,004.1% during the 3rd quarter. Quarry LP now owns 3,598 shares of the company’s stock worth $77,000 after buying an additional 3,427 shares during the last quarter. Canada Pension Plan Investment Board purchased a new stake in Progyny during the 2nd quarter worth about $77,000. Finally, New Age Alpha Advisors LLC acquired a new position in shares of Progyny during the 4th quarter worth about $94,000. Institutional investors and hedge funds own 94.93% of the company’s stock.

Insiders Place Their Bets

In other news, insider Geoffrey Clapp sold 1,530 shares of the business’s stock in a transaction that occurred on Tuesday, June 2nd. The stock was sold at an average price of $25.58, for a total value of $39,137.40. Following the transaction, the insider owned 59,117 shares of the company’s stock, valued at approximately $1,512,212.86. The trade was a 2.52% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, Director Kevin K. Gordon sold 5,500 shares of the company’s stock in a transaction that occurred on Wednesday, May 27th. The stock was sold at an average price of $24.99, for a total value of $137,445.00. Following the sale, the director owned 9,318 shares of the company’s stock, valued at $232,856.82. This trade represents a 37.12% decrease in their position. The SEC filing for this sale provides additional information. In the last 90 days, insiders have sold 36,916 shares of company stock valued at $939,875. 9.90% of the stock is owned by company insiders.

Analysts Set New Price Targets

A number of research analysts have recently commented on the company. KeyCorp dropped their price objective on Progyny from $32.00 to $28.00 and set an “overweight” rating on the stock in a report on Monday, March 2nd. Zacks Research downgraded Progyny from a “strong-buy” rating to a “hold” rating in a report on Friday, June 5th. Citigroup reiterated an “outperform” rating on shares of Progyny in a research note on Monday, May 11th. Jefferies Financial Group reissued a “buy” rating and set a $30.00 price objective on shares of Progyny in a report on Friday, March 6th. Finally, Barclays boosted their price objective on shares of Progyny from $23.00 to $27.00 and gave the stock an “overweight” rating in a research report on Friday, May 15th. Eleven investment analysts have rated the stock with a Buy rating and three have issued a Hold rating to the company. According to data from MarketBeat, the company currently has an average rating of “Moderate Buy” and a consensus target price of $29.67.

Progyny Stock Performance

Shares of NASDAQ:PGNY opened at $26.08 on Monday. Progyny, Inc. has a one year low of $16.10 and a one year high of $28.75. The stock has a market capitalization of $2.04 billion, a price-to-earnings ratio of 33.87, a PEG ratio of 2.30 and a beta of 1.03. The company has a 50-day simple moving average of $22.42 and a 200-day simple moving average of $22.28.

Progyny (NASDAQ:PGNY) last released its quarterly earnings results on Thursday, May 7th. The company reported $0.50 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.26 by $0.24. The firm had revenue of $328.50 million for the quarter, compared to analyst estimates of $326.46 million. Progyny had a return on equity of 13.34% and a net margin of 5.23%.The business’s revenue was down 26.4% on a year-over-year basis. During the same quarter last year, the company posted $0.17 earnings per share. Progyny has set its FY 2026 guidance at 1.980-2.09 EPS and its Q2 2026 guidance at 0.500-0.53 EPS. As a group, research analysts forecast that Progyny, Inc. will post 1.07 EPS for the current fiscal year.

Progyny announced that its board has approved a stock buyback program on Tuesday, May 26th that permits the company to repurchase $200.00 million in shares. This repurchase authorization permits the company to buy up to 10.3% of its stock through open market purchases. Stock repurchase programs are often a sign that the company’s board believes its shares are undervalued.

About Progyny

Progyny, Inc is a New York-based fertility benefits management company that partners with employers and health plans to design and administer comprehensive family-building programs. The company’s digital health platform integrates clinical expertise, patient support tools and data analytics to help members navigate fertility treatments, from in vitro fertilization (IVF) and egg freezing to surrogacy and adoption. By focusing on outcomes-based care, Progyny aims to improve success rates while controlling costs for its clients.

The core of Progyny’s offering is its proprietary Smart Cycle® benefit, which bundles clinical, emotional and logistical support into a single package.